J. Safra Sarasin Holding AG Has $15.23 Million Holdings in Insmed, Inc. $INSM

J. Safra Sarasin Holding AG raised its holdings in Insmed, Inc. (NASDAQ:INSM) by 1,342.2% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 93,181 shares of the biopharmaceutical company’s stock after buying an additional 86,720 shares during the period. J. Safra Sarasin Holding AG’s holdings in Insmed were worth $15,235,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. iA Global Asset Management Inc. raised its holdings in Insmed by 15,973.5% in the 4th quarter. iA Global Asset Management Inc. now owns 26,682 shares of the biopharmaceutical company’s stock valued at $4,644,000 after acquiring an additional 26,516 shares in the last quarter. Monashee Investment Management LLC acquired a new position in Insmed in the fourth quarter valued at about $8,702,000. Nordea Investment Management AB acquired a new position in Insmed in the fourth quarter valued at about $3,492,000. Darwin Global Management Ltd. lifted its position in Insmed by 5.8% during the third quarter. Darwin Global Management Ltd. now owns 20,457,445 shares of the biopharmaceutical company’s stock worth $2,897,797,000 after purchasing an additional 1,112,824 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH grew its stake in Insmed by 89.5% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 103,308 shares of the biopharmaceutical company’s stock worth $17,981,000 after buying an additional 48,779 shares in the last quarter.

Analyst Ratings Changes

Several research analysts have commented on INSM shares. Royal Bank Of Canada lowered their price objective on shares of Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a research note on Tuesday, April 21st. Stifel Nicolaus lifted their target price on Insmed from $205.00 to $208.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. JPMorgan Chase & Co. dropped their target price on shares of Insmed from $180.00 to $179.00 and set an “overweight” rating for the company in a report on Monday, June 8th. Finally, Morgan Stanley upgraded shares of Insmed from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $166.00 to $212.00 in a research note on Monday, March 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Insmed presently has a consensus rating of “Moderate Buy” and an average target price of $211.00.

Insider Buying and Selling

In other Insmed news, CFO Sara Bonstein sold 2,404 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total transaction of $245,857.08. Following the completion of the sale, the chief financial officer owned 69,082 shares of the company’s stock, valued at approximately $7,065,016.14. This represents a 3.36% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO William Lewis sold 10,699 shares of the business’s stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $117.40, for a total transaction of $1,256,062.60. Following the completion of the transaction, the chief executive officer owned 259,058 shares in the company, valued at $30,413,409.20. This trade represents a 3.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 65,289 shares of company stock valued at $7,334,073. Insiders own 2.10% of the company’s stock.

Insmed Stock Performance

NASDAQ:INSM opened at $115.61 on Monday. The stock’s 50-day moving average is $107.21 and its 200-day moving average is $138.01. Insmed, Inc. has a 1-year low of $90.39 and a 1-year high of $212.75. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. The stock has a market cap of $25.06 billion, a P/E ratio of -20.11 and a beta of 0.78.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.14. The firm had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The company’s revenue for the quarter was up 229.7% on a year-over-year basis. During the same quarter last year, the firm earned ($1.42) earnings per share. Equities research analysts anticipate that Insmed, Inc. will post -2.55 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.